Free Trial
NASDAQ:APLT

Applied Therapeutics Q4 2024 Earnings Report

Applied Therapeutics logo
$0.10 0.00 (0.00%)
As of 10/2/2026

Applied Therapeutics EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.18
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Applied Therapeutics Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
$0.61 million
Beat/Miss
Missed by -$615.00 thousand
YoY Revenue Growth
N/A

Applied Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, April 14, 2025
Conference Call Time
9:30AM ET

Applied Therapeutics Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Applied Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Applied Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Applied Therapeutics and other key companies, straight to your email.

About Applied Therapeutics

Applied Therapeutics (NASDAQ:APLT), Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and other conditions with limited therapeutic options. The company uses its expertise in carbohydrate metabolism and small-molecule drug development to pursue therapies for diseases affecting the nervous system and other organs.

Its lead investigational product is govorestat, also known as AT-007, an aldose reductase inhibitor being developed for classic galactosemia, a rare inherited metabolic disorder. Applied Therapeutics has also evaluated govorestat and other pipeline candidates in additional rare neurologic and metabolic conditions. These products remain subject to clinical and regulatory review, and the company does not currently have a broad commercial product portfolio.

Applied Therapeutics was founded in 2016 and is headquartered in New York. The company’s research and clinical-development programs have involved collaborations and studies spanning multiple geographic regions. Shoshana Shendelman, Ph.D., is the company’s founder and chief executive officer.

View Applied Therapeutics Profile